Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics' produ ...

Cytokinetics, Incorporated (CYTK) reported a net loss of $1.36 per share for the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.41. In the year-ago quarter, the company reported a net loss of $1.33 per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The year-over-year deterioration was due to higher operating expenses.Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and comme ...

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CYTK over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking ...

Cytokinetics (CYTK) 2025 Conference May 07, 2025 10:00 AM ET Speaker0 So I'm excited to be joined next at the Citizens Life Science Conference by Cytokinetics. Cytokinetics is a special specialty cardiology company with a focus on muscle biology. Really exciting time for the company with, Aficampton, PDUFA date. It's just several months away now. Obviously, lots of discussion over the last week about the the PDUFA extension, so we'll jump into that. But Robert and team just welcome and maybe I'll just ask y ...

Core Viewpoint - The Schall Law Firm is investigating Cytokinetics for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Cytokinetics issued false or misleading statements or failed to disclose important information to investors [2]. - A report from BioPharma Dive indicated that the FDA has delayed the approval decision for Cytokinetics' drug aficamten, which is intended for hypertrophic obstructive cardiomyopathy, to review the company's risk management plan [2]. - Following the news of the FDA's delay, Cytokinetics' shares dropped by over 12% during afternoon trading on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who have suffered losses are encouraged to contact the firm for a free discussion of their rights [3].

Cytokinetics (CYTK) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Diane Weiser - Senior Vice President of Corporate Communications & Investor RelationsRobert Blum - President and CEOAndrew Callos - Executive VP & Chief Commercial OfficerFady Malik - Executive Vice President of Research & DevelopmentStuart Kupfer - Senior VP & Chief Medical OfficerIsaac Ciechanover - EVP, Corporate Development and Chief Business OfficerSung Lee - Executive VP & CFOSean McCutcheon - Vice President - Biot ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 CYTOKINETICS, INCORPORATED (Exact name of registrant as specified in its charter) Delaware 94-3291317 ( ...

Cytokinetics (CYTK) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Diane Weiser - Senior Vice President of Corporate Communications & Investor RelationsRobert Blum - President and CEOAndrew Callos - Executive VP & Chief Commercial OfficerFady Malik - Executive Vice President of Research & DevelopmentStuart Kupfer - Senior VP & Chief Medical OfficerIsaac Ciechanover - EVP, Corporate Development and Chief Business OfficerSung Lee - Executive VP & CFOSean McCutcheon - Vice President - Biot ...

Cytokinetics (CYTK) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Diane Weiser - Senior Vice President of Corporate Communications & Investor RelationsRobert Blum - President and CEOAndrew Callos - Executive VP & Chief Commercial OfficerFady Malik - Executive Vice President of Research & DevelopmentStuart Kupfer - Senior VP & Chief Medical OfficerIsaac Ciechanover - EVP, Corporate Development and Chief Business OfficerSung Lee - Executive VP & CFOSean McCutcheon - Vice President - Biot ...

Cytokinetics (CYTK) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to Cytokinetics First Quarter twenty twenty five Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen only mode. At the company's request, we will open the call to questions after the presentation. We will allow for only one question per participant. I will now turn the call over to Diane Weiser, Cytokinetics' Senior Vice Pres ...